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Recurrence of steroid-resistant nephrotic syndrome in kidney trans.
plants is associated with increased acute renal failure and acute rejection.
We performed 73 kidney transplants in 51 patients with steroid-resistant
nephrotic syndrome (SRNS) with focal segmental glomerular sclerosis
(FSG) ages 18.4 12.8 (X SD) years. Recurrence of SRNS, defined
by rapid onset of proteinuria, hypoalbuminemia and/or >95% epithelial
cell foot process effacement with or without the presence of FSG,
occurred in 26 grafts in 16 patients. Acute renal failure (ARF) occurred
in 16 of 26 (61.5%) grafts with recurrence versus 7 of 47 (14.9%) grafts
without recurrence (P < 0.0001). ARF occurred in 4 of 9 (44.4%)
living-related donor (LRD) recipients with recurrence and 3 of 21
(12.5%) LRD recipients without recurrence (NS). ARF in cadaver
donor (CAD) recipients with recurrence was 12 of 17 (70.5%) versus 4
of 23 (17.4%) without recurrence (P < 0.0001). ARF was also higher in
LRD or CAD with recurrence than in a control group of non-SRNS
patients matched for age, sex and time of transplantation. Graft survival
at one year was lower in patients with recurrence and ARF [4 of 16
(25%)] compared to patients with recurrence and no ARF [9 of 11
(82%), P < 0.011. There was no difference in graft survival in patients
without recurrence who did or did not have ARF. One or more acute
rejection episodes occurred in all 16 patients with ARF and recurrence,
in all 7 patients with ARF without recurrence, and in 7 of 10 patients
with recurrence without ARF compared with only 11 of 40 (28%) of
patients with neither recurrence nor ARF (P < 0.0001, <0.001 and
<0.04, respectively). A loglinear model showed associations between
acute rejection and ARF (P < 0.01), recurrence and ARF (P = 0.05),
and recurrence and acute rejection (P < 0.025). Twelve of 16 (75%) of
grafts with both recurrence and ARF versus 4 of 40(10%) of grafts with
neither recurrence nor ARF were lost in association with acute rejec-
tion in the first two post-transplant years (P < 0.0001). Only one graft
was lost from recurrence of SRNS, per se. Thus, recurrence of SRNS
is associated with an increased incidence of ARF, and both ARF and
recurrence are associated with greater risks of acute rejection. The
increased graft loss in recurrence is primarily due to acute rejection. As
has been speculated for ARF, recurrence may result in graft changes
which stimulate acute rejection.
Patients transplanted for end-stage renal failure developing
consequent to steroid resistant nephrotic syndrome (SRNS)
with focal segmental glomerulosclerosis (FSG) are at risk for
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the development of recurrence of nephrotic syndrome in the
renal allograft [1—ill. We had previously reported that patients
whose primary renal disease took less than three years to
proceed from onset to terminal uremia and patients whose
native kidneys had diffuse or focal mesangial cell proliferation
were at increased risk of recurrence of proteinuria in the renal
allograft [8, 9]. We had also shown that these two variables,
rapid progression to terminal ure ia and mesangial prolifera-
tion, were frequently covariables [9]. In addition, we and others
have reported increased graft loss in patients with SRNS/FSG
and recurrent proteinuria in the renal allograft [3, 7—10]. How-
ever, the cause of this increased in graft loss has not been
completely explained. It is known that patients with nephrotic
syndrome can be at higher risk for acute renal failure (ARF)
[12—18] most often, as reviewed by Smith and Hayslett, accom-
panied by acute tubular necrosis (ATN) [18]. Further, it has
been suspected that ATN may be associated with an increased
risk of acute rejection in renal allograft recipients [19—211. We
had previously reported, based on a chart review study, that
about one-half of the graft loss in patients with recurrence was
due to rejection and one-half was due to recurrence per se [22].
However, in a study initiated to explore our clinical suspicion
suggesting a high frequency of ARF in patients with recurrent
SRNS, we encountered an inordinate incidence of acute rejec-
tion. This resulted in a complete re-analysis of our SRNS/FSG
patient material, including a review of all relevant renal allograft
pathology specimens. We report that patients with recurrence
of SRNS have a markedly increased rate of ARF and renal
allograft loss from rejection compared to patients without
recurrence and that these two transplant complications may be
separate risk factors.
Methods
Patients
Since 1965 we have performed 73 renal allograft transplants
in 51 patients (25 female) with SRNS/FSG. Their ages at the
time of initial transplantation was 18.4 12.8 years (X SD).
Thirty-three of these allografts were from living-related donors
(LRD) and 40 from cadaver donors (CAD). All of the patients
previously described in our papers detailing risk factors for
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Table 1. Criteria for recurrence of steroid-resistant nephrotic
syndrome in 26 grafts
Proteinuria and FSG + FPE 9
Proteinuria + FSG 7
Proteinuria + FPE 4
Proteinuria 5
FPE 1
Abbreviations are: FSG, focal segmental glomerular sclerosis; FPE,
foot process effacement.
recurrence of SRNS are represented here [8, 9, 22]. An addi-
tional 10 patients and 4 previously reported patients receiving
new grafts are also reported here.
We computer selected 67 grafts performed in 65 patients as
controls (C). Selection criteria included age 4 years, sex,
LRD versus CAD and primary versus subsequent grafts. Three
grafts in two control patients were eliminated from further
consideration because of their immediate loss from vascular
accidents. The number of mismatches for HLA-A and -B in the
SRNS/FSG patients (1.8 1.0 X SD, N = 67) and in the
controls (1.7 1.0, N = 60) did not differ. Similarly, HLA AB
+ DR mismatches in the SRNS/FSG patients (2.8 1.6, N =
46) and controls (2.6 1.6, N 40) were nearly identical.
Maximal panel reactivity exceeding 50% prior to transplanta-
tion of a given graft was present in 25% of SRNS patients and
26% of the controls. Reactivity exceeding 50% at the time of
transplantation was 13% in SRNS patients and 14% in the
controls. Further, by chi-square analysis, there were no signif-
icant differences in the likelihood of ATN in SRNS patients or
in controls with maximal or at transplant panel reactivity of
more than or less than 50%. Recurrence of SRNS (see below)
was not associated with increased panel reactivity or HLA
mismatches. Data describing donor age and preservation time
(cold ischemic time) were recorded for cadaver grafts and
analyzed as risk factors for ARF.
Definitions
Recurrent disease. Criteria for the classification of a renal
allograft as suffering recurrence (R) of SRNS included one or
more of: (1) clinical recurrence with the post-transplant devel-
opment of hypoalbuminemia (serum albumin <2.5 g/dl) and/or
proteinuria,  1 g/m2/24 hr, within 3 months of transplantation
in the absence of clinical or histological evidence of acute
rejection. All patients classified as recurrent disease based on
proteinuria had at least 5 g/24 hr of urinary protein; (2) histo-
logic recurrence with 95 to 100% foot process obliteration by
electron microscopy [8, 9]; no patients were classified as having
histologic recurrence with FSG by light microscopy in the
absence of proteinuria as defined above (Table 1).
Acute renal failure. ARF is defined as post-transplant renal
failure with oliguria ( 1 cc/kg/hr) and uremia requiring dialysis
support during the first post-transplant week. Patients were
judged not to have ARF if renal insufficiency was determined to
result from hyperacute, accelerated or acute rejection, or
vascular or urologic complications.
Acute rejection. The diagnosis of acute rejection was applied
only to patients meeting renal biopsy criteria which we have
previously described in detail [23]. Graft loss due to acute
rejection was defined as one or more biopsy-proven episodes of
acute renal allograft rejection resulting in sufficient loss of renal
function or perpetuation of primary nonfunction so as to require
chronic dialysis and/or retranspiantation.
Graft loss from recurrent FSG. To qualify for this category,
graft failure with advanced renal insufficiency would have
occurred in association with marked glomerular abnormalities
of FSG and global glomerular sclerosis in the absence of
pathologic findings of acute and chronic rejection. This criterion
strictly confines graft loss from recurrent FSG to situations in
which glomerular destruction from recurrent disease is clearly
the dominant reason for graft failure. The adoption of this strict
definition resulted in reclassification of some patients we had
previously reported as having had graft loss due to recurrent
disease [9, 22] to the categories of graft loss due to rejection.
The hospital records and renal pathologic materials from all
patients transplanted at the University of Minnesota with a
diagnosis of SRNS/FSG were reviewed. The clinical course of
each graft was characterized according to the criteria listed
above. In addition, other causes of graft dysfunction and graft
loss were noted.
Statistical analysis
Statistical analysis included chi-square, Student's t-test,
Fisher exact test, loglinear model associations and analysis of
variance (ANOVA). Values for P 0.05 were taken to be
statistically significant.
Results
Incidence and criteria for recurrence of SRNS
Twenty-six grafts in 16 patients were classified as having
recurrence of SRNS (Table 1). In 25 grafts the diagnosis was
based upon the documentation of heavy proteinuria in the first
three months post-transplantation. However, in 20 of these 25
grafts there was pathologic confirmation of this diagnosis, 7
having FSG, 9 having both FSG and extensive foot process
fusion and 4 having foot process fusion alone. Thus, in all 11
grafts classified as recurrence of SRNS by the presence of early
heavy proteinuria and where electron microscopic material was
available, the diagnosis was confirmed by the presence of
marked epithelial cell changes. Only in one case of primary
graft nonfunction was the diagnosis based on histologic criteria
alone, that of extensive foot process fusion (Table 1). FSG was
first detected on biopsies performed between 15 days and 2
years post-transplantation and extensive foot process fusion
was noted on biopsies performed within 7 days to 2 months
post-transplantation.
Sixteen of the 26 (61.5%) grafts in SRNS patients had ARF.
In 37 patients with 47 grafts that did not have recurrent SRNS,
the incidence of ARF was 14.9% (P = 0.0001, chi-square).
While the incidence of ARF in cadaver kidneys with recurrence
was significantly greater than in cadaver kidneys with no
recurrence (P = 0.002, Fisher exact test), this comparison did
not reach statistical significance for the LRD recipients (Table
2). LRD with recurrence and CAD with recurrence both had
higher incidences of ARF than their appropriate non-SRNS
controls (chi-square P <0.01 and <0.05, respectively, Table 2).
There were no significant differences in ARF comparing SRNS
patients without recurrence and their controls (Table 2).
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Table 2. Incidence of ARF in grafts transplanted for SRNS/FSG and
controls
Recurrence of
SRNS (N = 26)
ARF No ARF
No recurrence of
SRNS (N = 47)
ARF No ARF
Controls
ARF
(N = 64)
No ARF
LRD 4 (44.4) 5 (65.6) 3 (12.5) 21(87.5) 1(3.4) 28 (96.6)
CAD 12 (70.5) 5 (29.5) 4 (17.4) 19 (82.6) 12 (34.3) 23 (65.7)
Total 16 10 7 40 13 51
(61.5) (38.5) (14,9) (85.1) (20.3) (79.7)
Abbreviations are: ARF, acute renal failure; SRNSIFSG, steroid-
resistant nephrotic syndrome with focal segmental glomerular sclerosis;
LRD, living related donor; CAD, cadaver donor. Numbers in paren-
thesis = %.
There was a trend toward group effects of preservation time
on the risk of ARF (P = 0.074, ANOVA). Control group
cadaver recipients with ARF had longer preservation times (38
8 hr; N = 12) than those without ARF (25 12; N = 22; P <
0.005). There were no other significant group differences.
Donor age did not influence ARF risk (ANOVA P = 0.88).
Renal biopsies were performed during the ARF episodes in 9
renal allografts of SRNS patients between 4 and 30 (median 15)
days post-kidney transplantation. Since, in most cases these
biopsies were performed when ARF persisted beyond 10 to 14
days and since ARF was usually short lived, most patients did
not have biopsies during their ARF episodes. All showed
changes consistent with acute tubular necrosis (ATN). In one
case immediate post-transplant massive proteinuria was fol-
lowed, within 36 hours, by ARF. FSG lesions were noted at 15
days post-transplant (see above) and mild acute tubulointersti-
tial rejection was also noted. One graft showed ATN and
moderate acute tubulointerstitial rejection at 21 days post-
transplant. This was treated successfully. However, with re-
covery of graft function, there was increasing proteinuria and,
five weeks later, FSG lesions and diffuse foot process fusion
was noted on a repeat allograft biopsy.
Graft survival rates at one year and at final follow-up were
markedly reduced in grafts with recurrence and ARF compared
to grafts with recurrence without ARF (Table 3). However,
there was no difference in graft survival rates at one year or
long-term (beyond one year) in kidneys with no recurrence
comparing those with to those without ARF (Table 3). It is
noteworthy that only one of 16 grafts with recurrence and ARF
was functioning at the time of this analysis. Control patients
with ARF tended to have a lower one year graft survival rate,
but this did not reach statistical significance (Table 3). ARF was
also associated with a numerically lower long-term graft sur-
vival in controls but this was not statistically significant (Table
3).
Six of the 16 grafts with recurrence and ARF (3 in a single
patient) were lost when severe acute rejection ensued while the
patients were still receiving dialysis support for ARF (Table 4).
In two of these grafts massive proteinuria was documented
before ARF developed. Five patients had severe nephrotic
syndrome with massive proteinuria complicated by rejection
episodes and elevated serum creatinine values. This combina-
tion led to the patients being extremely ill and to the decision for
early graft removal. Chronic rejection, acute rejection and
death with functioning graft accounted for the other four graft
losses in patients with recurrence and ARF (Table 4). In
contrast, only one patient with recurrence without ARF re-
quired early graft removal for massive nephrotic syndrome and
early renal dysfunction (Table 4). Only one patient with recur-
rence of SRNS actually lost graft function primarily because of
destruction of the graft from the redevelopment of lesions of
FSG and global glomerular sclerosis without evidence of acute
or chronic rejection. The dominant causes of graft loss in
patients without recurrence included acute and chronic rejec-
tion, death with a functioning graft, and noncompliance (Table
4). As expected, most of the grafts that were lost in controls
were destroyed by acute or chronic rejection (Table 4).
All 16 patients with recurrence and ARF had one or more
acute rejection episodes in the first post-transplant year (Table
5). Also, the incidence of acute rejection was increased in
patients with recurrence but no ARF and in patients with ARF
without recurrence compared to the incidence in grafts with
neither of these complications (Table 5). A log linear model
revealed significant associations between recurrence and ARF
(P = 0.05), recurrence and rejection (P < 0.025), and rejection
and ARF (P < 0.01; Table 5). Thus, the incidence of acute
rejection was higher in those grafts with recurrence or ARF or
both compared to grafts with neither of these complications
(Table 5). Acute rejection in the first year was also more
common in controls with ARF than in SRNS grafts with neither
ARF nor recurrence. However, although numerically greater,
the incidence of acute rejection in control grafts with ARF was
not significantly different from that in control grafts without
ARF (Table 5).
Discussion
Our studies demonstrate a marked increase in the incidence
of ARF in patients documented to have recurrence of SRNS by
either clinical or histological criteria or both. This increased
incidence among SRNS patients was mainly seen in recipients
of cadaver kidneys with recurrent SRNS while a similar trend
amongst LRD recipients did not reach statistical significance.
However, compared to non-SRNS controls, the increase in
ARF in SRNS patients with recurrence was seen in both LRD
and CAD recipients. Our data do not allow for definitive
dissection as to whether recurrence of SRNS predisposes to
ARF or whether ARF is responsible for an increased incidence
of recurrence. However, reports of severe ARF occurring in the
native kidneys of patients with SRNS following relatively minor
provocative events [12—18] argue that the high incidence of
ARF seen in the current study may be consequent to recurrence
of SRNS. Certainly, recurrence was noted in the absence of
ARF in our patients, indicating that ARF is not a necessary
precondition for recurrence of SRNS in the renal allograft. The
mechanism(s) whereby recurrence of SRNS might predispose
to ARF is unknown. Glomerular filtration rate (GFR) is reduced
in patients with nephrotic syndrome [24, 25] and the reduction
in GFR is proportional to the severity of glomerular epithelial
foot process alterations [26]. Since a marked degree foot
process obliteration was seen in all of our patients with recur-
rence whose biopsies were studied by electron microscopy, it is
possible that these epithelial cell changes were associated with
reduced GFR. Under these circumstances, the additional renal
trauma related to the transplant process per se may have been
sufficient to produce the extreme decline in GFR which we
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Table 3. Survival rates of grafts with and without recurrence and in controls
Graft
survival
Recurrence No recurrence Controls
1 year
long
terma1 year
long
terma 1 year
long
terma
ARF
P value
No ARF
4/16 (25)
0.003
9/10 (90)
1/16 (6)
0.005
4/10 (40)
4/7 (57)
NS
35/40 (88)
4/7 (57)
NS
22/40 (55)
8/13 (62)
>.05 <.1
45/51 (88)
5/13 (38)
NS
28/51 (55)
Abbreviations are: SRNS, steroid resistant nephrotic syndrome; ARF, acute renal failure; NS, not significant. Numbers in parenthesis = %.
a Follow up = 5.3 4.6 (X SD) years
Table 4. Causes of graft loss
Cause
Total number of grafts
SRNS Controls
ARF
13
No ARF
51
RIARF
16
RINo ARF
10
NoRJARF
7
No RJNo ARF
40
ARF/Acute rejectiona
Severe NS/early RF/rejection
Chronic rejection
Acute rejection
Death with functioning graft
Recurrence of SRNS/FSGS
Stopped taking medication
6 (38)
5 (31)
2 (13)
1 (6)
1 (6)
—
—
—
1 (10)
2 (20)
1 (10)
1 (10)
1(10)
—
—
—
2 (29)
1(14)
—
—
—
—
11(28)
1(3)
5 (13)
—
1 (3)
—
4 (31)
1(8)
3 (23)
—
—
—
13 (25)
1(2)
6 (12)
—
1 (2)
Abbreviations are: RIARF, recurrence with acute renal failure; k/No ARF, recurrence without ARF; No RJARF, no recurrence with ARF; No
k/No ARF, no recurrence without ARF; NS, nephrotic syndrome; RF, renal failure; SRNS/FSG, steroid-resistant nephrotic syndrome with focal
segmental glomerular sclerosis. Numbers in parenthesis =
a Patients remaining dialysis dependent after ARF developed, followed by acute rejection
Table 5. Incidence of one or more acute rejection episodes in first
post-transplant year
Rejection episodes %
I Recurrence/ARF 16/16 (100)
II Recurrence/no ARF 7/10 (70)
III No recurrence/ARF 7/7 (100)
IV No recurrence/no ARF 11/40 (28)
V Controls/ARF 10/13 (77)
VI Controls/no ARF 27/51 (53)
I vs. IV, P <0.001; II vs. IV, P = 0.04; III vs. IV, P = 0.001; IV vs.
V. P = 0.03 by chi-square. No other comparisons were significant.
Loglinear model associations among SRNS patients are: recurrence and
ARF, P = 0.05; rejection and ARF, P < 0.01; recurrence and rejection,
P < 0.025.
defined as ARF. The greater incidence of ARF amongst cadaver
as compared to LRD recipients with recurrence of SRNS in our
study is consistent with this hypothesis. This increased inci-
dence could not be explained by influences of donor age or
preservation time of cadaver kidneys in SRNS patient.
This study confirmed our [8, 9] and others' [7, 10] previous
observations indicating reduced early and long-term survival
rates in grafts suffering from recurrence of SRNS. The current
study indicates that the highest incidence of graft loss occurred
in patients with both ARF and recurrence. In this group of 16
renal allografts, 15 were lost, 14 in association with rejection,
and 12 early in the post-transplant course. Six grafts with ARF
followed by acute rejection never functioned sufficiently to
allow the patient to become dialysis-independent following
transplantation. Of the 42 grafts in our series which were lost,
only one was lost primarily due to severe progression of focal
segmental and global glomerular sclerosis. The remainder were
primarily lost consequent to acute and chronic rejection. This
conclusion, somewhat at variance with our previous writings on
this subject [9, 23], derives from the current more strict
classification of graft loss due to recurrent SRNS/FSG as being
limited to patients without histologic evidence of serious acute
and/or chronic rejection but with advanced focal segmental and
global glomerular sclerosis. Further, the methodology of the
current study involved a review of all histologic materials,
resulting in some changes in the assignment of causes of graft
loss compared to our earlier studies which depended on chart
reviews.
Both recurrence of SRNS and ARF were independently
related to an increased incidence of one or more acute rejection
episodes in the first post-transplant year. An increase in the
incidence of acute rejection episodes with an associated in-
crease in early graft loss has been previously reported in
patients with post-transplant ARF [19—21], and our control
patients evidenced similar trends. In addition, our studies
indicate that SRNS recurrence, per se, is also associated with
increased acute rejection risk. The pathogenesis of this in-
creased acute rejection risk is unknown. Possibly acute renal
injury is associated with the increased immunogenicity of the
kidney [21], perhaps, as suggested by Shoskes, Parfrey and
Halloran, [27], through increased expression of MHC antigens
in the renal graft, leading to more efficient T cell recognition and
effector response [28, 29]. Thus, Shoskes et al demonstrated
increased MHC complex antigen expression in tubular epithe-
hal cells and in inflammatory interstitial cells in mouse kidneys
exposed to acute ischemic injury. Similarly, Muller et al found
increased expression of HLA antigens in kidneys with a variety
of glomerular disorders including in patients with SRNS/FSG
[30]. The possibility that increased renal antigenicity occurs
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This may be particularly true in patients with recurrence who
have suffered early loss of their first grafts. In this situation,
Stephanian et al reported that 5of8 of such patients developed
recurrent disease and lost a second renal allograft [231. Alter-
natively, and perhaps based on what may be more precise
predictive tests than heretofore available [311, treatments such
as plasmaphoresis [32, 33], perhaps beginning prior to trans-
plantation, should be considered for these high risk patients.
Second, great pains should be taken to prevent ARF following
renal transplantation. Third, once oliguria has developed, there
is little to be gained by aggressive fluid administration and
diuretic therapy (personal observations) and it is best to avoid
creating situations of fluid overload in such patients, with the
accompanying risks of pulmonary edema and severe hyperten-
sion. Fourth, the development of progressive post-transplant
oliguria and ARF in otherwise hemodynamically stable patients
with SRNS as their original disease should not lead to aggres-
sive and potentially dangerous interventions such as arteriog-
raphy or re-exploration, unless compelling evidence of a vas-
cular catastrophe can be confirmed by less invasive methods
such as an isotopic renal blood flow study. Fifth, SRNS patients
with ARF and poor renal function require aliograft biopsies
after 10 to 14 days and at similar intervals thereafter in order to
detect the early development of acute rejection since this latter
complication is difficult to diagnose in patients receiving dialy-
sis support and since the risk of rejection is especially high.
Finally, patients with recurrence of SRNS not having ARF
should also be followed very closely for the development of
acute rejection.
In summary, recurrence of steroid-resistant nephrotic syn-
drome is associated with a high risk of ARF, episodes of acute
rejection, and increased graft loss from rejection. The patho-
genic mechanisms underlying these clinical associations remain
to be elucidated.
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